Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

4.33

Today's Change

+0.12 (2.85%)

Day's Change

4.24 - 4.70

Trading Volume

6,275,717

Overview

Market Cap

1 Billion

Shares Outstanding

323 Million

Avg Volume

3,084,449

Avg Price (50 Days)

2.70

Avg Price (200 Days)

3.61

PE Ratio

-27.06

EPS

-0.16

Earnings Announcement

18-Aug-2025

Previous Close

4.21

Open

4.30

Day's Range

4.24 - 4.7

Year Range

1.43 - 8.975

Trading Volume

6,275,717

Price Change Highlight

1 Day Change

2.85%

5 Day Change

7.44%

1 Month Change

71.83%

3 Month Change

96.82%

6 Month Change

6.91%

Ytd Change

6.65%

1 Year Change

-33.28%

3 Year Change

612.04%

5 Year Change

188.67%

10 Year Change

188.67%

Max Change

188.67%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment